Ginkgo biloba extract inhibits oxidized low-density lipoprotein (oxLDL)-induced matrix metalloproteinase activation by the modulation of the lectin-like oxLDL receptor 1-regulated signaling pathway in human umbilical vein endothelial cells

J Vasc Surg. 2016 Jan;63(1):204-15.e1. doi: 10.1016/j.jvs.2014.05.098. Epub 2014 Jul 28.

Abstract

Background: The overexpression of matrix metalloproteinases (MMPs) induced by oxidized low-density lipoprotein (oxLDL) has been found in atherosclerotic lesions. Previous reports have identified that oxLDL, via the upregulation of lectin-like ox-LDL receptor 1 (LOX-1), modulates the expression of MMPs in endothelial cells. Ginkgo biloba extract (GbE), from Ginkgo biloba leaves, has often been considered as a therapeutic compound for cardiovascular and neurologic diseases. However, further investigation is needed to ascertain the probable molecular mechanisms underlying the antiatherogenic effects of GbE. The aim of this study was to investigate the effects of GbE on oxLDL-activated MMPs of human endothelial cells and to test the involvement of LOX-1 and protein kinase C (PKC)-α, extracellular signal-regulated kinase (ERK), and peroxisome proliferator-activated receptor-γ (PPAR-γ).

Methods: Human umbilical vein endothelial cells were stimulated with oxLDL, with or without GbE treatment. LOX-1 signaling and MMPs expression were tested by Western blotting or activity assay. Further, protein expression levels of PKC-α, ERK, nuclear factor-κB, and PPAR-γ were investigated by Western blotting.

Results: GbE inhibited the oxLDL-caused upregulation of MMP-1, MMP-2, and MMP-3. Pretreating with GbE reduced oxLDL-activated LOX-1 expression. Furthermore, pharmacologic inhibitors of free radicals, Ca(++), PKC, and GbE, inhibited the oxLDL-induced ERK and nuclear factor-κB activation. Lastly, GbE ameliorated the oxLDL-inhibited PPAR-γ function.

Conclusions: Data obtained in this study indicate that GbE actives its protective effects by regulating the LOX-1-mediated PKC-α/ERK/PPAR-γ/MMP pathway, resulting in the suppression of reactive oxygen species formation and, ultimately, the reduction of MMPs expression in endothelial cells treated with oxLDL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Ginkgo biloba* / chemistry
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / enzymology
  • Humans
  • Lipoproteins, LDL / pharmacology*
  • Matrix Metalloproteinase 1 / metabolism
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinase 3 / metabolism
  • Matrix Metalloproteinase Inhibitors / isolation & purification
  • Matrix Metalloproteinase Inhibitors / pharmacology*
  • Matrix Metalloproteinases, Secreted / metabolism*
  • NF-kappa B / metabolism
  • PPAR gamma / metabolism
  • Plant Extracts / isolation & purification
  • Plant Extracts / pharmacology*
  • Protein Kinase C-alpha / metabolism
  • Reactive Oxygen Species / metabolism
  • Scavenger Receptors, Class E / metabolism*
  • Signal Transduction / drug effects*

Substances

  • Lipoproteins, LDL
  • Matrix Metalloproteinase Inhibitors
  • NF-kappa B
  • OLR1 protein, human
  • PPAR gamma
  • Plant Extracts
  • Reactive Oxygen Species
  • Scavenger Receptors, Class E
  • oxidized low density lipoprotein
  • PRKCA protein, human
  • Protein Kinase C-alpha
  • Extracellular Signal-Regulated MAP Kinases
  • Matrix Metalloproteinases, Secreted
  • MMP3 protein, human
  • Matrix Metalloproteinase 3
  • MMP2 protein, human
  • Matrix Metalloproteinase 2
  • MMP1 protein, human
  • Matrix Metalloproteinase 1